These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 25239496)

  • 1. Long-term treatment with tenofovir in Asian-American chronic hepatitis B patients is associated with abnormal renal phosphate handling.
    Tien C; Xu JJ; Chan LS; Chang M; Lim C; Lee S; Huh B; Shinada S; Bae HS; Fong TL
    Dig Dis Sci; 2015 Feb; 60(2):566-72. PubMed ID: 25239496
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improvement of bone mineral density and markers of proximal renal tubular function in chronic hepatitis B patients switched from tenofovir disoproxil fumarate to tenofovir alafenamide.
    Fong TL; Lee BT; Tien A; Chang M; Lim C; Ahn A; Bae HS
    J Viral Hepat; 2019 May; 26(5):561-567. PubMed ID: 30576085
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Altered Underlying Renal Tubular Function in Patients With Chronic Hepatitis B Receiving Nucleos(t)ide Analogs in a Real-World Setting: The MENTE Study.
    Rodríguez-Nóvoa S; García-Samaniego J; Prieto M; Calleja JL; Pascasio JM; Delgado Blanco M; Crespo J; Buti M; Bonet Vidal ML; Arenas Ruiz Tapiador J; Fernández-Rodríguez C; Solá R; Fraga E; González Diéguez L; Núñez O; Praga M; Del Pino-Montes J; Romero-Gómez M; Morillas R; Diago M; Castro Á;
    J Clin Gastroenterol; 2016 Oct; 50(9):779-89. PubMed ID: 27332746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Real-World Study on Safety and Efficacy of TAF Treatment in HBV Patients with High Risk of Osteoporosis or Osteopenia in China.
    Li C; Li H; Gong M; Liu Y; Zhang R; Geng J; Wang H; Yu Z; Wang Z; Liu X; Wei J
    Altern Ther Health Med; 2024 Sep; 30(9):146-151. PubMed ID: 38294749
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renal and bone side effects of long-term use of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide fumarate in patients with Hepatitis B: a network meta-analysis.
    Liu Z; Zhao Z; Ma X; Liu S; Xin Y
    BMC Gastroenterol; 2023 Nov; 23(1):384. PubMed ID: 37950196
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved bone and renal safety in younger tenofovir disoproxil fumarate experienced chronic hepatitis B patients after switching to tenofovir alafenamide or entecavir.
    Da Wang F; Zhou J; Li LQ; Li YJ; Wang ML; Tao YC; Zhang DM; Wang YH; Chen EQ
    Ann Hepatol; 2023; 28(5):101119. PubMed ID: 37271480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiviral therapy and the development of osteopenia/osteoporosis among Asians with chronic hepatitis B.
    Wei MT; Le AK; Chang MS; Hsu H; Nguyen P; Zhang JQ; Wong C; Wong C; Cheung R; Nguyen MH
    J Med Virol; 2019 Jul; 91(7):1288-1294. PubMed ID: 30776311
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monotherapy with tenofovir disoproxil fumarate for adefovir-resistant vs. entecavir-resistant chronic hepatitis B: A 5-year clinical trial.
    Lim YS; Gwak GY; Choi J; Lee YS; Byun KS; Kim YJ; Yoo BC; Kwon SY; Lee HC
    J Hepatol; 2019 Jul; 71(1):35-44. PubMed ID: 30876946
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naïve patients with chronic hepatitis B.
    Lok AS; Trinh H; Carosi G; Akarca US; Gadano A; Habersetzer F; Sievert W; Wong D; Lovegren M; Cohen D; Llamoso C
    Gastroenterology; 2012 Sep; 143(3):619-628.e1. PubMed ID: 22643350
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel evidence of serial changes of bone mineral density in chronic hepatitis B patients treated with entecavir.
    Huang PY; Chiu SY; Chang KC; Tseng PL; Yen YH; Tsai MC; Wang JH; Kee KM; Chen CH; Hung CH; Chiu KW; Hu TH
    Hepatol Int; 2021 Apr; 15(2):310-317. PubMed ID: 33907949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term Nucleotide Analogue Treatment Has Higher Levels of Renal Toxicities than Does Entecavir in Patients with Chronic Hepatitis B.
    Cho YY; Chang Y; Nam JY; Cho H; Cho EJ; Lee JH; Yu SJ; Yoon JH; Kim YJ
    Gut Liver; 2020 Mar; 14(2):225-231. PubMed ID: 31060115
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness and safety of switching to entecavir hepatitis B patients developing kidney dysfunction during tenofovir.
    Viganò M; Loglio A; Labanca S; Zaltron S; Castelli F; Andreone P; Messina V; Ganga R; Coppola N; Marrone A; Russello M; Marzano A; Tucci A; Taliani G; Fasano M; Fagiuoli S; Villa E; Bronte F; Santantonio T; Brancaccio G; Occhipinti V; Facchetti F; Grossi G; Rumi M; Lampertico P
    Liver Int; 2019 Mar; 39(3):484-493. PubMed ID: 30525275
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tenofovir alafenamide as compared to tenofovir disoproxil fumarate in the management of chronic hepatitis B with recent trends in patient demographics.
    Hsu YC; Wei MT; Nguyen MH
    Expert Rev Gastroenterol Hepatol; 2017 Nov; 11(11):999-1008. PubMed ID: 28965428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renal tubular dysfunction during long-term adefovir or tenofovir therapy in chronic hepatitis B.
    Gara N; Zhao X; Collins MT; Chong WH; Kleiner DE; Jake Liang T; Ghany MG; Hoofnagle JH
    Aliment Pharmacol Ther; 2012 Jun; 35(11):1317-25. PubMed ID: 22506503
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment with tenofovir disoproxil fumarate or entecavir in chronic hepatitis B virus-infected patients with renal impairment: results from a 7-year, multicentre retrospective cohort study.
    Lampertico P; Berg T; Buti M; Pathil A; Petersen J; Ryder SD; Zoulim F; Botros I; Flaherty JF; Jump B; Op den Brouw ML; van Troostenburg A; Ramroth H;
    Aliment Pharmacol Ther; 2020 Aug; 52(3):500-512. PubMed ID: 32583915
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B.
    Papatheodoridis GV; Dalekos GN; Idilman R; Sypsa V; Van Boemmel F; Buti M; Calleja JL; Goulis J; Manolakopoulos S; Loglio A; Papatheodoridi M; Gatselis N; Veelken R; Lopez-Gomez M; Hansen BE; Savvidou S; Kourikou A; Vlachogiannakos J; Galanis K; Yurdaydin C; Esteban R; Janssen HLA; Berg T; Lampertico P
    J Hepatol; 2020 Nov; 73(5):1037-1045. PubMed ID: 32553667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment Outcome and Renal Safety of 3-Year Tenofovir Disoproxil Fumarate Therapy in Chronic Hepatitis B Patients with Preserved Glomerular Filtration Rate.
    Min IS; Lee CH; Shin IS; Lee NE; Son HS; Kim SB; Seo SY; Kim SH; Kim SW; Lee SO; Lee ST; Kim IH
    Gut Liver; 2019 Jan; 13(1):93-103. PubMed ID: 30400723
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluating the renal safety of tenofovir disoproxil fumarate in hepatitis B patients without chronic kidney disease.
    Tsai HJ; Chuang YW; Yang SS; Chang YZ; Chang HR; Lee TY
    J Viral Hepat; 2021 Nov; 28(11):1579-1586. PubMed ID: 34464999
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Longitudinal trends in renal function in chronic hepatitis B patients receiving oral antiviral treatment.
    Udompap P; Kim D; Ahmed A; Kim WR
    Aliment Pharmacol Ther; 2018 Dec; 48(11-12):1282-1289. PubMed ID: 30370967
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tenofovir disoproxil fumarate vs adefovir dipivoxil in Chinese patients with chronic hepatitis B after 48 weeks: a randomized controlled trial.
    Hou JL; Gao ZL; Xie Q; Zhang JM; Sheng JF; Cheng J; Chen CW; Mao Q; Zhao W; Ren H; Tan DM; Niu JQ; Chen SJ; Pan C; Tang H; Wang H; Mao YM; Jia JD; Ning Q; Xu M; Wu SM; Li J; Zhang XX; Ji Y; Dong J; Li J
    J Viral Hepat; 2015 Feb; 22(2):85-93. PubMed ID: 25243325
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.